Real World Evidence of the Efficacy and Safety of FOQUEST

NCT04152629 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

257

Enrollment

INDUSTRY

Sponsor class

Conditions

Attention Deficit-Hyperactivity Disorder

Interventions

DRUG: Methylphenidate Hydrochloride
DRUG: Lisdexamfetamine Dimesylate

Sponsor

Purdue Pharma, Canada